Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results

Figure 3

Progression-free (PFS) and overall survival (OS) according to age and chemotherapy regimen. (A) PFS according to age and chemotherapy regimen (<70 and ≥70 years); (B) PFS according to age and chemotherapy regimen (<75 and ≥75 years); (C) OS according to age and chemotherapy regimen (<70 and ≥70 years); (D) OS according to age and chemotherapy regimen (<75 and ≥75 years). FU/CAP: 5-fluorouracil-/capecitabine-based chemotherapy; OS: overall survival, OX/IRI: oxaliplatin-/irinotecan-based chemotherapy, PFS: progression-free survival.

Back to article page